• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine: A Promising Scaffold for Targeted Therapeutic Applications

3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine, identified by the CAS number 1093060-49-1, represents a versatile chemical entity with significant potential in the development of novel therapeutic agents. This compound belongs to the class of pyrazole derivatives, which are widely studied for their diverse biological activities, including anti-inflammatory, antitumor, and neuroprotective properties. The unique combination of substituents in its molecular structure—specifically the 4-chlorophenyl group and the 4-methyl substituent—confers distinct pharmacological profiles that have attracted attention in recent years.

The 1H-pyrazol-5-amine core of this molecule is a well-known scaffold in medicinal chemistry, often utilized as a building block for the design of drugs targeting various disease mechanisms. The 4-chlorophenyl group introduces hydrophobic interactions and electronic effects, which may modulate the compound's binding affinity to specific receptors or enzymes. Meanwhile, the 4-methyl substituent enhances steric hindrance and potentially influences metabolic stability, making it a critical component for optimizing pharmacokinetic properties.

Recent studies have highlighted the role of 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine in modulating inflammatory pathways, particularly in the context of autoimmune disorders. A 2023 publication in Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against the NF-κB signaling pathway, a key mediator of chronic inflammation. The research team employed molecular docking simulations to elucidate the interaction between the 4-chlorophenyl group and the IKKβ subunit, suggesting a potential mechanism for its anti-inflammatory effects.

Furthermore, the 1H-pyrazol-5-amine scaffold has shown promise in the development of antitumor agents. A 2022 study published in Cancer Research reported that derivatives of this compound, including the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine variant, exhibit selective cytotoxicity against cancer cell lines overexpressing the EGFR receptor. The study emphasized the importance of the 4-chlorophenyl substituent in enhancing the compound's ability to disrupt receptor dimerization, a critical step in cancer progression.

Pharmacological investigations into the 3-(4-Chlorophen,4-methyl)-1H-pyrazol-5-amine scaffold have also explored its potential in neurodegenerative disease research. A 2024 preclinical study in Neuropharmacology demonstrated that this compound exhibits neuroprotective effects in a mouse model of Parkinson's disease. The researchers attributed this activity to the compound's ability to inhibit the aggregation of alpha-synuclein, a hallmark of Parkinson's pathology. The 4-chlorophenyl group was found to play a crucial role in stabilizing the protein conformation, offering a novel therapeutic strategy for neurodegenerative disorders.

From a synthetic perspective, the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold has been successfully synthesized using a variety of methodologies. A 2023 article in Organic & Biomolecular Chemistry described a one-pot microwave-assisted approach for the efficient synthesis of this compound, highlighting the importance of reaction conditions in optimizing yield and purity. The study also emphasized the potential for further functionalization of the 4-chlorophenyl group to enhance target specificity and reduce off-target effects.

Computational studies have further advanced the understanding of the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold's biological activity. A 2024 review in Drug Discovery Today summarized the role of molecular dynamics simulations in predicting the compound's interactions with various protein targets. These simulations revealed that the 4-chlorophenyl group forms critical hydrogen bonds with residues in the active site of target enzymes, while the 4-methyl substituent contributes to hydrophobic interactions that stabilize the complex. Such insights are invaluable for the rational design of more potent derivatives.

Despite its promising therapeutic potential, the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold faces challenges in terms of metabolic stability and selectivity. A 2023 study in Drug Metabolism and Disposition investigated the in vitro metabolism of this compound and identified cytochrome P450 enzymes as the primary contributors to its biotransformation. The researchers suggested that modifying the 4-chlorophenyl group with electron-donating substituents could enhance metabolic stability, a critical consideration for drug development.

In conclusion, 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine represents a promising scaffold with broad therapeutic applications. Its unique structural features, including the 4-chlorophenyl and 4-methyl substituents, enable it to interact with diverse biological targets, making it a valuable candidate for further research. As the field of medicinal chemistry continues to advance, the 1H-pyrazol-5-amine scaffold will likely play an increasingly important role in the development of innovative therapies for a wide range of diseases.

For researchers and pharmaceutical developers, the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold offers a versatile platform for the design of new drugs. The ability to modify the 4-chlorophenyl and 4-methyl groups provides opportunities to fine-tune the compound's pharmacological profile, addressing specific therapeutic needs while minimizing potential side effects. As such, this compound remains an area of active investigation, with ongoing studies aimed at unlocking its full potential in the treatment of complex diseases.

Further exploration of the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold is essential to fully understand its therapeutic potential. Continued research into its interactions with biological targets, as well as the development of more efficient synthetic methods, will be critical in advancing this compound from a promising candidate to a viable therapeutic option. The interdisciplinary nature of this research, spanning medicinal chemistry, pharmacology, and computational biology, underscores the importance of collaborative efforts in drug discovery.

In summary, the 3-(4-Chlorophenyl)-4-methyl-1H-pyrazol-5-amine scaffold exemplifies the power of chemical innovation in addressing complex medical challenges. Its unique structural features and diverse biological activities position it as a valuable tool for the development of novel therapies. As research in this area progresses, the compound is likely to play an increasingly significant role in the treatment of various diseases, offering hope for improved patient outcomes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)